iBio Secures $26M Financing, Extends Cash Runway to Q3 FY2028 and Delivers 100-Day Half-Life Data
iBio raised $26M in a private placement led by Frazier Life Sciences, extending its cash runway into Q3 FY2028 with $52.7M in cash on hand. The company presented non-human primate data for IBIO-610 showing a predicted 100-day half-life and plans IBIO-600 Phase 1a trials in H1 2026.
1. $26M Private Placement Financing
iBio completed a $26 million private placement led by Frazier Life Sciences, generating $24.4 million net proceeds. With $52.7 million in cash and investments as of December 31, 2025, the financing extends the cash runway into the third quarter of fiscal year 2028.
2. IBIO-610 Preclinical Progress
The company presented non-human primate data for its activin E antibody candidate IBIO-610, showing a predicted human half-life of up to 100 days. Ongoing CMC development and toxicology studies remain on track to support first human trials in early 2027.
3. IBIO-600 Advancement Toward Phase 1a
Toxicology studies for the myostatin antibody IBIO-600 are nearing completion, positioning the program for Phase 1a clinical trials in the first half of 2026. Development efforts also continue for bispecific myostatin×activin A and amylin candidates.
4. Q2 Fiscal 2026 Financial Results
For the quarter ended December 31, 2025, revenue was $0 versus $0.2 million in the prior-year period. R&D expenses rose to $4.3 million from $1.9 million, and G&A expenses increased to $5.2 million from $2.7 million, reflecting higher research activities and an asset impairment.